Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" COCP shares. View COCP analyst ratings or view top-rated stocks .

What is Cocrystal Pharma's stock price target for 2024?

1 analysts have issued 12 month price objectives for Cocrystal Pharma's stock. Their COCP share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price. View analysts price targets for COCP or view top-rated stocks among Wall Street analysts .

How have COCP shares performed in 2024?

Cocrystal Pharma's stock was trading at $1.7222 at the beginning of 2024. Since then, COCP shares have decreased by 15.2% and is now trading at $1.46. View the best growth stocks for 2024 here .

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,000 shares, an increase of 35.1% from the March 15th total of 3,700 shares. Based on an average daily volume of 13,900 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are sold short. View Cocrystal Pharma's Short Interest .

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our COCP earnings forecast .

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its earnings results on Thursday, March, 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.13.

When did Cocrystal Pharma's stock split?

Cocrystal Pharma's stock reverse split on the morning of Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA) , Hello Group (MOMO) , Intra-Cellular Therapies (ITCI) , Impala Platinum (IMPUY) , GenMark Diagnostics (GNMK) , Gevo (GEVO) , Auxly Cannabis Group (CBWTF) , Bionano Genomics (BNGO) , Blink Charging (BLNK) and Bilibili (BILI) .

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free COCP Stock Alerts

$1.46

+0.05 (+3.70%)

(As of 03:42 PM ET)

Compare

Today's Range: $1.35
▼
$1.52
50-Day Range: $1.40
▼
$1.60
52-Week Range: $1.33
▼
$3.29

Volume: 19,163 shs
Average Volume: 13,947 shs
Market Capitalization: $14.85 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.00

Get Cocrystal Pharma alerts:

Cocrystal Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 584.9% Upside
$10.00 Price Target
Short Interest: Healthy
0.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.71
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.18) to ($1.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

475th out of 930 stocks

Pharmaceutical Preparations Industry

218th out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Cocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cocrystal Pharma has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.07% of the float of Cocrystal Pharma has been sold short.
Short Interest Ratio / Days to Cover
Cocrystal Pharma has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cocrystal Pharma has recently increased by 35.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cocrystal Pharma does not currently pay a dividend.
Dividend Growth
Cocrystal Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COCP.

2.1

News and Social Media Coverage

News Sentiment
Cocrystal Pharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for COCP on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
25.06% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 6.72% of the stock of Cocrystal Pharma is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Cocrystal Pharma are expected to grow in the coming year, from ($2.18) to ($1.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cocrystal Pharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cocrystal Pharma is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cocrystal Pharma has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

COCP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

COCP Stock News Headlines

April 9, 2024 | americanbankingnews.com

Cocrystal Pharma, Inc. (NASDAQ:COCP) to Post Q1 2024 Earnings of ($0.56) Per Share, HC Wainwright Forecasts

April 8, 2024 | americanbankingnews.com

Q1 2024 EPS Estimates for Cocrystal Pharma, Inc. (NASDAQ:COCP) Boosted by HC Wainwright

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

April 6, 2024 | americanbankingnews.com

HC Wainwright Comments on Cocrystal Pharma, Inc.'s Q1 2025 Earnings (NASDAQ:COCP)

April 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Cocrystal Pharma (COCP) and Icecure Medical (ICCM)

March 28, 2024 | msn.com

COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023

March 28, 2024 | finanznachrichten.de

Cocrystal Pharma, Inc.: Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

March 28, 2024 | benzinga.com

Recap: Cocrystal Pharma Q4 Earnings

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

March 28, 2024 | globenewswire.com

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

March 20, 2024 | finanznachrichten.de

Cocrystal Pharma, Inc.: Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

March 19, 2024 | markets.businessinsider.com

Cocrystal Pharma Receives Pre-IND Feedback Regarding CC-42344 - Quick Facts

March 19, 2024 | globenewswire.com

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

February 24, 2024 | investing.com

Cocrystal Pharma Inc (COCP)

February 20, 2024 | finance.yahoo.com

COCP: Cocrystal Pharma provides updates on its clinical programs.

February 11, 2024 | morningstar.com

Cocrystal Pharma Inc COCP

January 4, 2024 | finance.yahoo.com

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

December 26, 2023 | benzinga.com

Cocrystal Pharma Stock (NASDAQ:COCP), Analyst Ratings, Price Targets, Predictions

December 26, 2023 | benzinga.com

Cocrystal Pharma Stock (NASDAQ:COCP) Dividends: History, Yield and Dates

December 6, 2023 | finance.yahoo.com

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

November 29, 2023 | finance.yahoo.com

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

November 27, 2023 | finance.yahoo.com

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

November 14, 2023 | benzinga.com

Cocrystal Pharma Stock (NASDAQ:COCP) Earnings Dates and Earning Calls

November 14, 2023 | msn.com

COCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.

November 13, 2023 | benzinga.com

Recap: Cocrystal Pharma Q3 Earnings

November 13, 2023 | finance.yahoo.com

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

November 9, 2023 | finance.yahoo.com

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

See More Headlines

Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/28/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:COCP
CUSIP: N/A
CIK: 1412486
Web: www.cocrystalpharma.com
Phone: (305) 425-1780
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.00
High Stock Price Target: $10.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +584.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,980,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -59.62%
Return on Assets: -54.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.92
Quick Ratio: 8.92

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.59 per share
Price / Book: 0.56

Miscellaneous

Outstanding Shares: 10,170,000
Free Float: 7,624,000
Market Cap: $14.85 million
Optionable: Not Optionable
Beta: 1.34

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Roger D. Kornberg Ph.D. (Age 77)
Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
Comp: $125k
Dr. Sam Lee Ph.D. (Age 64)
Co-Founder, Co-CEO & President
Comp: $521.38k

Key Competitors

View All Competitors

COCP Stock Analysis - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" COCP shares.
View COCP analyst ratings or view top-rated stocks.
What is Cocrystal Pharma's stock price target for 2024?: 1 analysts have issued 12 month price objectives for Cocrystal Pharma's stock. Their COCP share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 584.9% from the stock's current price.
View analysts price targets for COCP or view top-rated stocks among Wall Street analysts.
How have COCP shares performed in 2024?: Cocrystal Pharma's stock was trading at $1.7222 at the beginning of 2024. Since then, COCP shares have decreased by 15.2% and is now trading at $1.46.
View the best growth stocks for 2024 here.
Are investors shorting Cocrystal Pharma?: Cocrystal Pharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,000 shares, an increase of 35.1% from the March 15th total of 3,700 shares. Based on an average daily volume of 13,900 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the shares of the company are sold short.
View Cocrystal Pharma's Short Interest.
When is Cocrystal Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our COCP earnings forecast.

How were Cocrystal Pharma's earnings last quarter?: Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its earnings results on Thursday, March, 28th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.13.
When did Cocrystal Pharma's stock split?: Cocrystal Pharma's stock reverse split on the morning of Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What other stocks do shareholders of Cocrystal Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).
How do I buy shares of Cocrystal Pharma?: Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COCP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial